【摘要】 晚期肺癌疗效甚差，其综合治疗仍是目前临床研究的重点，对２３例失去手术机会的晚期肺癌进行支气管动脉灌注化疗（ＢＡＩ）和肿瘤体内局部免疫肿瘤即双介入治疗（Ａ组），并与同期肺癌１２例单纯瘤体内局部免疫治疗（Ｂ组）、１６例单纯ＢＡＩ化疗（Ｃ组）、１８例传统化疗（Ｄ组）比较疗效，Ａ组完全缓解（ＣＲ）２例，部分缓解（ＰＲ）１８例，近期有效率ＣＲ＋ＰＲ８６．９６％，明显优于Ｂ组ＣＲ＋ＰＲ５０．００％，Ｃ组ＣＲ＋ＰＲ５６．２５％和Ｄ组ＣＲ＋ＰＲ３３．３３％，差异有统计学意义（χ２＝１２．８２１，Ｐ＜０．０１）。Ａ组７例重获Ⅱ期手术适应症，２例手术切除术后病理显示癌细胞大片变性、坏死。单纯局部免疫治疗方法简单，近期疗效接近Ｃ、Ｄ两组，毒副作用少，双介入治疗晚期肺癌具有较大的应用价值，为晚期肺癌提供了新的有效、简便的治疗方法。更多还原

【Abstract】 The therapeutic effectiveness of advanced lung cancer is unsatisfied, and the combined treatment is still a focal point of clinical research. In this study, 23 imoperable patients with advanced lung cancer were treated with both perfusion of chemotherapeutic agents into bronchial artery and intratumoral interleukin-2 immunotherapy(group A); And the results were compared with those obtained from 12 patients with only intratumoral immunotherapy (group B), 16 patients with only perfusion of chemotherapautic agents into bronchial artery(proup C), and 18 patients with traditional systemic chemotherapy(group D), respectively. Two cases with complete remission and 18 partial resmission were observed in group A, the overall effective rate(86.96%) was significantly higher than Those in group B(50.00%)、 group C(56.25%)、 and group D(33.33%), respectively (P all<0.05). Intratumoral immunotherapy was proved to be simple, convenient and effective in the treatment of advanced lung cancer. Combination of intratumoral immunotherapy and intrabronchial artery chemotherapy may be an alternative for advanced lung cancer.更多还原